Eli Lilly’s antibody therapy has become the first experimental COVID-19 treatment to win an emergency use authorization (EUA) from the FDA.
The treatment, bamlanivimab, is intended for patients who do not need to be hospitalized but have several risk factors for developing a serious form of the illness, such as age.
Lilly reported positive results from a study that showed the treatment could reduce the rate of hospitalization in coronavirus patients.
The company is already prepped to crank out 1 million doses of the treatment by the end of the year. The U.S. government has already purchased 300,000 doses and plans to offer them to Americans for free.
Read the full Reuters report.
